OppenheimerFunds Inc. Has $444,000 Position in Albany Molecular Research, Inc. (AMRI)

OppenheimerFunds Inc. increased its stake in shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) by 79.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,607 shares of the biotechnology company’s stock after buying an additional 14,033 shares during the period. OppenheimerFunds Inc.’s holdings in Albany Molecular Research were worth $444,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Comerica Bank increased its position in Albany Molecular Research by 5.7% in the fourth quarter. Comerica Bank now owns 24,940 shares of the biotechnology company’s stock valued at $452,000 after buying an additional 1,349 shares in the last quarter. State Street Corp increased its position in Albany Molecular Research by 7.2% in the fourth quarter. State Street Corp now owns 512,819 shares of the biotechnology company’s stock valued at $9,623,000 after buying an additional 34,448 shares in the last quarter. Renaissance Technologies LLC increased its position in Albany Molecular Research by 3.1% in the fourth quarter. Renaissance Technologies LLC now owns 357,900 shares of the biotechnology company’s stock valued at $6,714,000 after buying an additional 10,658 shares in the last quarter. Thrivent Financial for Lutherans increased its position in Albany Molecular Research by 4.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 11,990 shares of the biotechnology company’s stock valued at $225,000 after buying an additional 550 shares in the last quarter. Finally, Teachers Advisors LLC increased its position in Albany Molecular Research by 0.5% in the fourth quarter. Teachers Advisors LLC now owns 41,916 shares of the biotechnology company’s stock valued at $786,000 after buying an additional 198 shares in the last quarter. 73.82% of the stock is currently owned by hedge funds and other institutional investors.

Albany Molecular Research, Inc. (NASDAQ AMRI) opened at 21.66 on Tuesday. The company’s market cap is $901.14 million. Albany Molecular Research, Inc. has a 12 month low of $13.01 and a 12 month high of $22.17. The firm has a 50-day moving average price of $20.05 and a 200 day moving average price of $17.34.

Albany Molecular Research (NASDAQ:AMRI) last posted its earnings results on Tuesday, May 9th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.01. The company had revenue of $163.80 million during the quarter, compared to analysts’ expectations of $161.43 million. Albany Molecular Research had a positive return on equity of 11.97% and a negative net margin of 11.26%. The firm’s quarterly revenue was up 55.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.07 earnings per share. Equities research analysts predict that Albany Molecular Research, Inc. will post $1.13 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://sportsperspectives.com/2017/07/18/oppenheimerfunds-inc-has-444000-position-in-albany-molecular-research-inc-amri.html.

AMRI has been the topic of several analyst reports. Morgan Stanley downgraded Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 target price on the stock. in a research report on Thursday, May 11th. They noted that the move was a valuation call. William Blair reaffirmed an “outperform” rating on shares of Albany Molecular Research in a research report on Tuesday, May 23rd. J P Morgan Chase & Co downgraded Albany Molecular Research from an “overweight” rating to a “neutral” rating in a research report on Thursday, June 8th. Finally, First Analysis downgraded Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a research report on Monday, June 12th.

About Albany Molecular Research

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply